Riskpilot← Back to searchSign inGet full accessDicot Pharma AB
ABActiveOrg 5590063490S:T Olofsgatan 11 AResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20151-4 employees
Revenue 2024
SEK 0
EBITDA margin
—
-32% vs 2023
Equity ratio
90.3%
Financial strength
Net profit 2024
SEK -57,7M
-31% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -59,2M | -32% |
| Net profit | SEK -57,7M | -31% |
| Total assets | SEK 123,6M | +131% |
| Equity | SEK 111,7M | +152% |
| Employees | — | — |
Legal name
Dicot Pharma AB
Org number
5590063490
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
5 mars 2015
Share capital
SEK 12 451 000
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska direkt eller indirekt, bedriva forskning, utveckling, marknadsföring och försäljning av läkemedel och därmed förenlig verksamhet.
Address
S:T Olofsgatan 11 A
Email
info@dicot.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | −6 | −19 | −787 | −6 358 | −13 325 | −17 542 | −27 163 | −31 715 | −44 997 | −59 247 |
| Depreciation & amort. | −64 | −103 | −210 | −0 | −0 | −2 | −8 | −8 | −8 | −6 |
| EBIT | −70 | −122 | −997 | −6 358 | −13 325 | −17 544 | −27 171 | −31 723 | −45 005 | −59 253 |
| Net financials | −1 | −2 | 5 | 14 | −71 | 2 | −4 | −33 | 782 | 1 547 |
| Profit before tax | −71 | −123 | −991 | −6 343 | −13 396 | −17 541 | −27 175 | −31 756 | −44 157 | −57 696 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −71 | −123 | −991 | −6 343 | −13 396 | −17 541 | −27 175 | −31 756 | −44 157 | −57 696 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 1 312 | 4 009 | 3 313 | 9 972 | 14 071 | 21 610 | 31 768 | 12 371 | 53 555 | 123 622 |
| Equity | 231 | 2 928 | 1 939 | 8 287 | 12 801 | 19 659 | 28 351 | 5 358 | 44 393 | 111 667 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 1 081 | 1 081 | 1 374 | 1 684 | 1 269 | 1 951 | 3 417 | 7 013 | 9 163 | 11 955 |
| Total debt | 1 081 | 1 081 | 1 374 | 1 684 | 1 269 | 1 951 | 3 417 | 7 013 | 9 163 | 11 955 |
EBITDA margin
-5924700000.0%
This company
15.8%
Market median
-37498101366% vs market
20152024
Equity ratio
90.3%
This company
38.2%
Market median
+136% vs market
20152024
Return on equity
-51.7%
This company
18.4%
Market median
-381% vs market
20152024
Net profit margin
-5769600000.0%
This company
8.1%
Market median
-71229629730% vs market
20152024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20152024
Debt / equity
0.11×
This company
0.62×
Market median
+82% vs market
20152024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-03-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
LG Chief Auditor | Chief Auditor | 2020 | — | — |
EV Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
GB Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2022 | — | — | |
| Chairman | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2021 | — | — | |
| Chairman | 2021 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Dicot Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lars Gustaf Kylberg | Chief Auditor | 0 companies |
| Elin Viktoria Trampe | Chief Executive Officer | 0 companies |
| Göran Beijer | Chief Executive Officer | 0 companies |
| Michael Lars Åke Gustav Zell | Board of Directors | 0 companies |
| Lars Olov Jonsson | Chairman | 0 companies |
| Curt Mikael von Euler-Chelpin | Board of Directors | 0 companies |
| Lena Carina Söderström | Board of Directors | 0 companies |
| Jarl Erik Sylvester Wikberg | Board of Directors | 0 companies |
| Per-Göran Gillberg | Board of Directors | 0 companies |
| Claes Tomas Post | Board of Directors | 0 companies |
| Fredrik Franz Johan Wilhelm Buch | Board of Directors | 0 companies |
| Jan-Eric Österlund | Board of Directors | 0 companies |
| Eva Ulrika Saers | Chairman | 0 companies |